Preimplantation genetic testing for aneuploidies (PGT-A) analyzes embryos created through in vitro fertilization (IVF) to identify chromosomal abnormalities. This process helps select embryos with the typical number of chromosomes, increasing the chances of a successful pregnancy and reducing the risk of miscarriage or genetic conditions related to chromosome number. For instance, it can detect conditions like Down syndrome (Trisomy 21). Results typically classify embryos as euploid (normal chromosome number), aneuploid (abnormal chromosome number), or mosaic (a mixture of normal and abnormal cells).
Choosing chromosomally normal embryos contributes to higher implantation rates, reduces the time to pregnancy, and minimizes the emotional and financial burden associated with multiple IVF cycles. The development of this technology represents a significant advance in reproductive medicine, offering prospective parents increased control and confidence in their journey to parenthood. While the initial clinical application focused on maternal age-related aneuploidy risk, its utility has expanded to encompass other indications, like recurrent pregnancy loss and repeated implantation failure.
